Latest News and Press Releases

North American feasibility study demonstrated the utility, safety and efficacy of the alfapump in the management of patients with recurrent and refractory ascites GHENT, Belgium, June 16, 2020 ...

GHENT, Belgium, May 04, 2020 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart...

Continued strong progress in U.S. NASH-related and global heart failure programs Successfully raised €19 million in Q1 2020 extending cash runway into H1 2021 Conference call with live webcast...

Positive pre-clinical and clinical proof-of-concept data of Sequana Medical’s innovative DSR therapy published in top tier peer-reviewed cardiovascular journal Data demonstrates potential for...

The study aims to: Evaluate the safety of alfapump DSR in patients with heart failureAssess the feasibility of alfapump DSR to remove excess sodium and fluid from the bodyExplore the potential impact...

Continued strong progress since IPO in February 2019: Commenced POSEIDON pivotal study to support approval of the alfapump® in the U.S. & CanadaAchieved clinical proof-of-concept of Direct Sodium...

Study aims to support the approval of the alfapump in U.S. and CanadaResults anticipated by mid-2021U.S. launch of the alfapump planned for H1 2022 GHENT, Belgium, Sept. 25, 2019 (GLOBE NEWSWIRE)...

Dr. Butler, Dr. Costanzo, Dr. Tang and Dr. Testani to advise on alfapump® DSR development               GHENT, Belgium, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext...

alfapump pivotal study for treatment of recurrent or refractory ascites due to liver cirrhosisOptimised clinical trial design of up to 50 patients implanted with alfapump in study cohort and shorter...

First-in-human single dose DSR study meets primary and secondary endpoints Direct Sodium Removal (DSR) was safe & well-tolerated Substantially higher sodium removal with DSR vs standard Peritoneal...